Endonovo Therapeutics, Inc. (ENDV): R&D Expense
Not updated since 2022-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$0
Year ended 2021-12-31
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2021-12-31 | $0 | -100.0% | 2022-04-14, From 2021-01-01 |
| 2020-12-31 | $3.3K | -97.9% | 2022-04-14, From 2020-01-01 |
| 2019-12-31 | $153.1K | -44.2% | 2021-04-13, From 2019-01-01 |
| 2018-12-31 | $274.3K | +138.2% | 2020-05-04, From 2018-01-01 |
| 2017-12-31 | $115.2K | n/a | 2019-04-15, From 2017-01-01 |
| 2016-12-31 | $0 | n/a | 2018-04-06, From 2016-01-01 |